Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Study Identifies Genes Linked to Autoimmune Kidney Disease

By LabMedica International staff writers
Posted on 14 Mar 2017
A pair of genes linked to serum levels of the defective immunoglobulin galactose-deficient IgA1 has been identified during a genome-wide association study (GWAS) and may serve as biomarkers to help diagnose the autoimmune kidney disease IgA nephropathy (IgAN), or Berger's disease.

IgAN occurs when the mutated form of the antibody immunoglobulin A (IgA) causes inflammation of the glomeruli, which impedes the kidneys' ability to filter waste from the blood. More...
The primary molecular defect in individuals with IgAN is abnormal O-glycosylation of IgA antibodies. O-glycosylation is a common type of post-translational modification of proteins; specific abnormalities in the mechanism of O-glycosylation have been implicated in cancer, inflammatory, and blood diseases. However, the molecular basis of abnormal O-glycosylation in these complex disorders is not known.

Investigators at the Columbia University Medical Center used a simple lectin-based ELISA assay, based on a GalNAc-specific lectin from Helix aspersa (HAA), to determine the levels of circulating Gd-IgA1 in sera from 2,633 people of European and East Asian ancestry, populations with high rates of the disease. Results obtained with this assay, revealed that serum levels of Gd-IgA1 represented a normally distributed quantitative trait in healthy populations, but up to two thirds of IgAN patients had levels above the 95th percentile for healthy controls.

The screen identified two genome-wide significant loci in the C1GALT1 and C1GALT1C1 genes. These genes encode molecular partners essential for enzymatic O-glycosylation of IgA1. These two loci explained approximately 7% of variability in circulating Gd-IgA1 in Europeans, but only 2% in East Asians. Moreover, many healthy family members exhibited very high Gd-IgA1 levels, identifying elevated Gd-IgA1 as a heritable risk factor that preceded the development of IgAN.

"Very little is known about the causes of IgAN, genetic or otherwise, so our discovery represents an important step toward developing better therapies for this disease," said first author Dr. Krzysztof Kiryluk, assistant professor of medicine at Columbia University Medical Center. "Since approximately 50% of variability in Gd-IgA1 levels is due to genetic factors, this means that about 43% of the genetic variability is still unexplained. We started with a relatively small study population, so explaining 7% of variability between individuals with the disease was a good start. As we analyze more patients, we expect that we will find more genetic variants and can begin to piece together how these variants interact with environmental factors to cause disease."

The study was published in the February 10, 2017, online edition of the journal PLOS Genetics.


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Portable Electronic Pipette
Mini 96
New
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
New
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.